SPH Qingdao Growful Pharmaceutical Co., Ltd.

Clinical trials sponsored by SPH Qingdao Growful Pharmaceutical Co., Ltd., explained in plain language.

Now part of Shanghai Pharmaceuticals Holding Co., Ltd. 601607 SSE

A pharmaceutical company manufacturing and distributing drugs, a subsidiary of Shanghai Pharmaceuticals.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1

Can a traditional chinese tablet reduce heart attacks and hospitalizations?

Disease control Recruiting now

This study tests whether Yangxinshi tablets can improve outcomes for people with coronary heart disease and heart dysfunction. About 2,700 participants aged 40-80 will receive the tablet or a placebo. The goal is to see if the tablets reduce serious heart events like death, strok…

Phase 4 • Sponsor: SPH Qingdao Growful Pharmacetical Co.,Ltd • Aim: Disease control

Last updated Jun 27, 2026 07:59 UTC

SPH Qingdao Growful Pharmaceutical Co., Ltd.

Can a traditional chinese tablet reduce heart attacks and hospitalizations?